Pharmacogenetic predictors for EGFR-inhibitor-associated skin toxicity
Autor: | Tanusree Paul, Julia C. Stingl, Stefan Boeck, Stefan Rüdiger, Volker Heinemann, Angela Seeringer, Sumit Parmar, Thomas Seufferlein, Volker Kächele, Christian Schumann |
---|---|
Rok vydání: | 2011 |
Předmět: |
Male
Oncology medicine.medical_specialty Class I Phosphatidylinositol 3-Kinases Cetuximab Pharmacology Antibodies Monoclonal Humanized Erlotinib Hydrochloride Phosphatidylinositol 3-Kinases Gefitinib Neoplasms Internal medicine Genetics Humans Medicine Epidermal growth factor receptor Protein Kinase Inhibitors Genetic Association Studies EGFR inhibitors integumentary system biology business.industry Panitumumab Antibodies Monoclonal Exanthema Middle Aged Rash ErbB Receptors Haplotypes Quinazolines biology.protein Molecular Medicine Female Erlotinib medicine.symptom business Pharmacogenetics medicine.drug |
Zdroj: | The Pharmacogenomics Journal. 13:181-188 |
ISSN: | 1473-1150 1470-269X |
DOI: | 10.1038/tpj.2011.51 |
Popis: | The aim of this study was to investigate pharmacogenetic determinants of skin rash associated with epidermal growth factor receptor (EGFR) inhibitor treatment. A total of 109 prospectively sampled cancer patients, receiving the first treatment with an EGFR inhibitor, were genotyped for functional EGFR polymorphisms and tagging variants in genes involved in receptor downstream signaling. Skin rash was absent in 26 (23.9%) patients and associated with shorter overall survival compared with patients presenting skin rash (P=0.005). The EGFR polymorphisms, 497G/A (P=0.008), and the haplotypes of the promoter variants, EGFR-216G/T and -191C/A (P=0.029), were associated with the appearance of skin rash. In addition, a common haplotype in the PIK3CA gene was associated with skin rash (P=0.045) and overall survival (P=0.009). In conclusion, genetic variation within the EGFR gene and its downstream signaling partner PIK3CA might predict EGFR-inhibitor-related skin rash. |
Databáze: | OpenAIRE |
Externí odkaz: |